Office of Research and Innovation

April 4, 2019 | Sasha Campbell

NIRvana Sciences, Inc., the leading developer of synthetic bacteriochlorins and chlorins, today announced that it has been awarded a $3 Million Phase IIb SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). This multi-year Phase IIb grant, “New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry,” will be used to accelerate development and commercialization of a new class of fluorescent dyes emitting between 700nm-1000nm that will increase the performance capabilities of flow cytometers. Flow cytometry is a heavily used instrumentation platform for understanding our body’s immune system. With many new NIRvana dyes, researchers and clinicians will be able to run more complex experiments enabling them to develop a better understanding of how our immune system fights infectious diseases and cancers leading to the faster development of new, more effective vaccines and drugs.

“NIRvana Sciences is very proud that NIAID sees the potential in our dyes for advancing infectious disease research, and that they also see the greater positive impact to the broader field of life sciences. Our novel synthetic chemistry platform combined with our ability to tune the spectral features of our dyes, makes it highly unique in creating many new dye colors” says CEO Russell Thomas. “Additionally, we look forward to using this grant to complete development and scale-up of our chemistry for commercial sales to reagent companies.”

NIRvana Sciences is based upon research licensed from North Carolina State University. In November, NIRvana Sciences moved into a new facility at Alexandria Innovation Center in Research Triangle Park, NC to support further expansion of their chemistry efforts.

About NIRvana Sciences
NIRvana Sciences mission is to commercialize red and near-infrared fluorescent dyes with narrow spectral properties for use in life science diagnostics and imaging applications. In addition to support from NIH, NIRvana has also received support from angel investors in North and South Carolina, North Carolina Biotech Center (NCBC), NC IDEA and Blackstone
Entrepreneurs Network.

For additional information, please visit

Comments are closed.

« NC State Spinout Locus Biosciences Inks Historic Licensing Deal
NIRSleep — a startup led by an NC State alumnus, former employee — wins $25,000 in 2019 Lulu eGames »